Investor Relations

Company Overview

We are a biotechnology company dedicated to developing treatments for certain medical conditions. Currently, we have two programs focused on kidney disease that we believe have the potential to offer medical benefit. As we grow the Company and build our team, we intend to focus on identifying medical conditions within and outside of kidney disease. Our current development programs are focused on the development of two novel therapies: Oxylanthanum Carbonate (OLC), for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494 for the treatment of acute kidney injury.

Upcoming Event

29th International Conference on Advances in Critical Care Nephrology AKI and CRRT 2024

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2022

Stock Inforamtion

IR Contacts

Company

Unicycive Therapeutics, Inc.
4300 El Camino Real
Suite 210
Los Altos, CA 94022
T: 650-351-4495
info@unicycive.com

Investor Relations

T: 650-543-5470
ir@unicycive.com

Transfer Agent

Philadelphia Stock Transfer, Inc.
2320 Haverford Road
Ardmore, PA 19003

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.